Bessemer Group Inc Nektar Therapeutics Transaction History

Bessemer Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$2.03 - $4.28 $0 - $0	0 New	0 $0
Q4 2019 Feb 04, 2020	SELL	$15.87 - $23.12 $2,539 - $3,699	-160 Closed	0 $0
Q3 2019 Nov 07, 2019	SELL	$16.91 - $36.27 $2,790 - $5,984	-165 Reduced 50.77%	160 $3,000
Q2 2019 Jul 19, 2019	SELL	$31.0 - $36.3 $11,005 - $12,886	-355 Reduced 52.21%	325 $12,000
Q1 2019 May 13, 2019	BUY	$31.58 - $46.35 $1,894 - $2,781	60 Added 9.68%	680 $23,000
Q4 2018 Feb 12, 2019	BUY	$30.43 - $56.65 $18,258 - $33,990	600 Added 3000.0%	620 $20,000
Q2 2018 Jul 25, 2018	BUY	$46.25 - $104.45 $925 - $2,089	20 New	20 $1,000

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $193M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

Stay updated on Bessemer Group Inc with notifications on news.